ArticleScience advances2025
Picoeukaryote-based biohybrid microrobots for active delivery in the kidney.
Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Red Blood Cells as Endogenous Biotweezers for Optical Micromanipulation In Vivo.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Magnetically guided biohybrid microrobots with multimodal locomotion for barrier penetration and multifunctional tumor treatment.Microsystems & nanoengineering · 2026Article
- Light force-powered cellular medical micromachines.Frontiers in bioengineering and biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Confined spaces in the human body pose substantial challenges for biomedical procedures. Navigating these ultrasmall environments is essential for precise drug delivery, improving treatment outcomes and reducing adverse effects. Microrobots offer a promising approach to accessing these complex microenvironments. Here, we show a biohybrid microrobot based on picoeukaryotes, engineered as a cargo carrier for active delivery in tight in vivo spaces. The microrobot exhibits strong in vitro motility through narrow two-dimensional and complex three-dimensional networks and, in vivo, achieves outstanding kidney penetration, uniform distribution, and >48-hour retention while resisting flow shear and immune clearance, with excellent biosafety. Their ability to retain functionality and sustain propulsion within the confined and complex kidney vasculatures and interstitial spaces underscore their potential for long-term, active delivery in confined biological environments. The picoeukaryote-based biohybrid microrobot system represents a major advancement in active drug delivery, especially tailored to the challenging microenvironments of the kidney.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.